Tp53 and its potential therapeutic role as a target in bladder cancer

Chiara Ciccarese, Francesco Massari, Ana Blanca, Giampaolo Tortora, Rodolfo Montironi, Liang Cheng, Marina Scarpelli, Maria R. Raspollini, Nuno Vau, Jorge Fonseca, Antonio Lopez-Beltran

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Introduction: Despite more than 30 years of research on p53 resulting in >50,000 publications, we are now beginning to figure out the complexity of the p53 pathway, gene ontology and conformational structure of the molecule. Recent years brought great advances in p53 related drugs and the potencial ways in which p53 is inactivated in cancer. Areas covered: We searched for related publications on Pubmed and ClinicalTrial.gov using the following keywords ‘p53, Tp53, p53 and bladder cancer, p53 and therapeutic target’. Relevant articles improved the understanding on p53 pathways and their potential as candidate to targeted therapy in bladder cancer. Expert opinion: Novel strategies developed to restore the function of mutants with chemical chaperones or by using compounds to improved pharmacokinetic properties are in development with potential to be applied in the oncology clinic. Other strategies targeting aberrantly overexpressed p53 regulators with wild-type p53 are also an active area of research. In particular, studies inhibiting the interaction of p53 with its negative regulators MDMX and MDM2 are an important field in drug discovery. Small molecules for inhibition of MDM2 are now in clinical trials process. However, personalized anticancer therapy might eventually advance through analyses of p53 status in cancer patients.

Original languageEnglish (US)
Pages (from-to)401-414
Number of pages14
JournalExpert Opinion on Therapeutic Targets
Volume21
Issue number4
DOIs
StatePublished - Apr 3 2017

Fingerprint

Urinary Bladder Neoplasms
Molecules
Pharmacokinetics
Oncology
Ontology
Gene Ontology
Genes
p53 Genes
Expert Testimony
Drug Discovery
Research
PubMed
Publications
Neoplasms
Therapeutics
Clinical Trials
Pharmaceutical Preparations

Keywords

  • bladder cancer
  • oncotarget
  • P53
  • personalized medicine
  • TP53

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Cite this

Ciccarese, C., Massari, F., Blanca, A., Tortora, G., Montironi, R., Cheng, L., ... Lopez-Beltran, A. (2017). Tp53 and its potential therapeutic role as a target in bladder cancer. Expert Opinion on Therapeutic Targets, 21(4), 401-414. https://doi.org/10.1080/14728222.2017.1297798

Tp53 and its potential therapeutic role as a target in bladder cancer. / Ciccarese, Chiara; Massari, Francesco; Blanca, Ana; Tortora, Giampaolo; Montironi, Rodolfo; Cheng, Liang; Scarpelli, Marina; Raspollini, Maria R.; Vau, Nuno; Fonseca, Jorge; Lopez-Beltran, Antonio.

In: Expert Opinion on Therapeutic Targets, Vol. 21, No. 4, 03.04.2017, p. 401-414.

Research output: Contribution to journalReview article

Ciccarese, C, Massari, F, Blanca, A, Tortora, G, Montironi, R, Cheng, L, Scarpelli, M, Raspollini, MR, Vau, N, Fonseca, J & Lopez-Beltran, A 2017, 'Tp53 and its potential therapeutic role as a target in bladder cancer', Expert Opinion on Therapeutic Targets, vol. 21, no. 4, pp. 401-414. https://doi.org/10.1080/14728222.2017.1297798
Ciccarese, Chiara ; Massari, Francesco ; Blanca, Ana ; Tortora, Giampaolo ; Montironi, Rodolfo ; Cheng, Liang ; Scarpelli, Marina ; Raspollini, Maria R. ; Vau, Nuno ; Fonseca, Jorge ; Lopez-Beltran, Antonio. / Tp53 and its potential therapeutic role as a target in bladder cancer. In: Expert Opinion on Therapeutic Targets. 2017 ; Vol. 21, No. 4. pp. 401-414.
@article{2ca7cad701be4dea959df48260a1db9e,
title = "Tp53 and its potential therapeutic role as a target in bladder cancer",
abstract = "Introduction: Despite more than 30 years of research on p53 resulting in >50,000 publications, we are now beginning to figure out the complexity of the p53 pathway, gene ontology and conformational structure of the molecule. Recent years brought great advances in p53 related drugs and the potencial ways in which p53 is inactivated in cancer. Areas covered: We searched for related publications on Pubmed and ClinicalTrial.gov using the following keywords ‘p53, Tp53, p53 and bladder cancer, p53 and therapeutic target’. Relevant articles improved the understanding on p53 pathways and their potential as candidate to targeted therapy in bladder cancer. Expert opinion: Novel strategies developed to restore the function of mutants with chemical chaperones or by using compounds to improved pharmacokinetic properties are in development with potential to be applied in the oncology clinic. Other strategies targeting aberrantly overexpressed p53 regulators with wild-type p53 are also an active area of research. In particular, studies inhibiting the interaction of p53 with its negative regulators MDMX and MDM2 are an important field in drug discovery. Small molecules for inhibition of MDM2 are now in clinical trials process. However, personalized anticancer therapy might eventually advance through analyses of p53 status in cancer patients.",
keywords = "bladder cancer, oncotarget, P53, personalized medicine, TP53",
author = "Chiara Ciccarese and Francesco Massari and Ana Blanca and Giampaolo Tortora and Rodolfo Montironi and Liang Cheng and Marina Scarpelli and Raspollini, {Maria R.} and Nuno Vau and Jorge Fonseca and Antonio Lopez-Beltran",
year = "2017",
month = "4",
day = "3",
doi = "10.1080/14728222.2017.1297798",
language = "English (US)",
volume = "21",
pages = "401--414",
journal = "Expert Opinion on Therapeutic Targets",
issn = "1472-8222",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - Tp53 and its potential therapeutic role as a target in bladder cancer

AU - Ciccarese, Chiara

AU - Massari, Francesco

AU - Blanca, Ana

AU - Tortora, Giampaolo

AU - Montironi, Rodolfo

AU - Cheng, Liang

AU - Scarpelli, Marina

AU - Raspollini, Maria R.

AU - Vau, Nuno

AU - Fonseca, Jorge

AU - Lopez-Beltran, Antonio

PY - 2017/4/3

Y1 - 2017/4/3

N2 - Introduction: Despite more than 30 years of research on p53 resulting in >50,000 publications, we are now beginning to figure out the complexity of the p53 pathway, gene ontology and conformational structure of the molecule. Recent years brought great advances in p53 related drugs and the potencial ways in which p53 is inactivated in cancer. Areas covered: We searched for related publications on Pubmed and ClinicalTrial.gov using the following keywords ‘p53, Tp53, p53 and bladder cancer, p53 and therapeutic target’. Relevant articles improved the understanding on p53 pathways and their potential as candidate to targeted therapy in bladder cancer. Expert opinion: Novel strategies developed to restore the function of mutants with chemical chaperones or by using compounds to improved pharmacokinetic properties are in development with potential to be applied in the oncology clinic. Other strategies targeting aberrantly overexpressed p53 regulators with wild-type p53 are also an active area of research. In particular, studies inhibiting the interaction of p53 with its negative regulators MDMX and MDM2 are an important field in drug discovery. Small molecules for inhibition of MDM2 are now in clinical trials process. However, personalized anticancer therapy might eventually advance through analyses of p53 status in cancer patients.

AB - Introduction: Despite more than 30 years of research on p53 resulting in >50,000 publications, we are now beginning to figure out the complexity of the p53 pathway, gene ontology and conformational structure of the molecule. Recent years brought great advances in p53 related drugs and the potencial ways in which p53 is inactivated in cancer. Areas covered: We searched for related publications on Pubmed and ClinicalTrial.gov using the following keywords ‘p53, Tp53, p53 and bladder cancer, p53 and therapeutic target’. Relevant articles improved the understanding on p53 pathways and their potential as candidate to targeted therapy in bladder cancer. Expert opinion: Novel strategies developed to restore the function of mutants with chemical chaperones or by using compounds to improved pharmacokinetic properties are in development with potential to be applied in the oncology clinic. Other strategies targeting aberrantly overexpressed p53 regulators with wild-type p53 are also an active area of research. In particular, studies inhibiting the interaction of p53 with its negative regulators MDMX and MDM2 are an important field in drug discovery. Small molecules for inhibition of MDM2 are now in clinical trials process. However, personalized anticancer therapy might eventually advance through analyses of p53 status in cancer patients.

KW - bladder cancer

KW - oncotarget

KW - P53

KW - personalized medicine

KW - TP53

UR - http://www.scopus.com/inward/record.url?scp=85014894094&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014894094&partnerID=8YFLogxK

U2 - 10.1080/14728222.2017.1297798

DO - 10.1080/14728222.2017.1297798

M3 - Review article

VL - 21

SP - 401

EP - 414

JO - Expert Opinion on Therapeutic Targets

JF - Expert Opinion on Therapeutic Targets

SN - 1472-8222

IS - 4

ER -